487 related articles for article (PubMed ID: 19414255)
1. Structure-based design of 3-aryl-6-amino-triazolo[4,3-b]pyridazine inhibitors of Pim-1 kinase.
Grey R; Pierce AC; Bemis GW; Jacobs MD; Moody CS; Jajoo R; Mohal N; Green J
Bioorg Med Chem Lett; 2009 Jun; 19(11):3019-22. PubMed ID: 19414255
[TBL] [Abstract][Full Text] [Related]
2. Hit to lead evaluation of 1,2,3-triazolo[4,5-b]pyridines as PIM kinase inhibitors.
Pastor J; Oyarzabal J; Saluste G; Alvarez RM; Rivero V; Ramos F; Cendón E; Blanco-Aparicio C; Ajenjo N; Cebriá A; Albarrán MI; Cebrián D; Corrionero A; Fominaya J; Montoya G; Mazzorana M
Bioorg Med Chem Lett; 2012 Feb; 22(4):1591-7. PubMed ID: 22266039
[TBL] [Abstract][Full Text] [Related]
3. The design, synthesis, and biological evaluation of PIM kinase inhibitors.
Tsuhako AL; Brown DS; Koltun ES; Aay N; Arcalas A; Chan V; Du H; Engst S; Franzini M; Galan A; Huang P; Johnston S; Kane B; Kim MH; Laird AD; Lin R; Mock L; Ngan I; Pack M; Stott G; Stout TJ; Yu P; Zaharia C; Zhang W; Zhou P; Nuss JM; Kearney PC; Xu W
Bioorg Med Chem Lett; 2012 Jun; 22(11):3732-8. PubMed ID: 22542012
[TBL] [Abstract][Full Text] [Related]
4. Discovery of novel triazolo[4,3-b]pyridazin-3-yl-quinoline derivatives as PIM inhibitors.
Martínez-González S; Rodríguez-Arístegui S; Gómez de la Oliva CA; Hernández AI; González Cantalapiedra E; Varela C; García AB; Rabal O; Oyarzabal J; Bischoff JR; Klett J; Albarrán MI; Cebriá A; Ajenjo N; García-Serelde B; Gómez-Casero E; Cuadrado-Urbano M; Cebrián D; Blanco-Aparicio C; Pastor J
Eur J Med Chem; 2019 Apr; 168():87-109. PubMed ID: 30802730
[TBL] [Abstract][Full Text] [Related]
5. Identification and structure-activity relationship of 8-hydroxy-quinoline-7-carboxylic acid derivatives as inhibitors of Pim-1 kinase.
Sliman F; Blairvacq M; Durieu E; Meijer L; Rodrigo J; Desmaële D
Bioorg Med Chem Lett; 2010 May; 20(9):2801-5. PubMed ID: 20363627
[TBL] [Abstract][Full Text] [Related]
6. Design and synthesis of triazolopyridazines substituted with methylisoquinolinone as selective c-Met kinase inhibitors.
Ryu JW; Han SY; Yun JI; Choi SU; Jung H; Ha JD; Cho SY; Lee CO; Kang NS; Koh JS; Kim HR; Lee J
Bioorg Med Chem Lett; 2011 Dec; 21(23):7185-8. PubMed ID: 22001029
[TBL] [Abstract][Full Text] [Related]
7. Discovery of novel pyrazolo[1,5-a]pyrimidines as potent pan-Pim inhibitors by structure- and property-based drug design.
Wang X; Magnuson S; Pastor R; Fan E; Hu H; Tsui V; Deng W; Murray J; Steffek M; Wallweber H; Moffat J; Drummond J; Chan G; Harstad E; Ebens AJ
Bioorg Med Chem Lett; 2013 Jun; 23(11):3149-53. PubMed ID: 23623490
[TBL] [Abstract][Full Text] [Related]
8. Identification of triazolopyridazinones as potent p38α inhibitors.
Herberich B; Jackson C; Wurz RP; Pettus LH; Sherman L; Liu Q; Henkle B; Saris CJ; Wong LM; Chmait S; Lee MR; Mohr C; Hsieh F; Tasker AS
Bioorg Med Chem Lett; 2012 Jan; 22(2):1226-9. PubMed ID: 22196117
[TBL] [Abstract][Full Text] [Related]
9. Kinase domain inhibition of leucine rich repeat kinase 2 (LRRK2) using a [1,2,4]triazolo[4,3-b]pyridazine scaffold.
Galatsis P; Henderson JL; Kormos BL; Han S; Kurumbail RG; Wager TT; Verhoest PR; Noell GS; Chen Y; Needle E; Berger Z; Steyn SJ; Houle C; Hirst WD
Bioorg Med Chem Lett; 2014 Sep; 24(17):4132-40. PubMed ID: 25113930
[TBL] [Abstract][Full Text] [Related]
10. A crystallographic fragment screen identifies cinnamic acid derivatives as starting points for potent Pim-1 inhibitors.
Schulz MN; Fanghänel J; Schäfer M; Badock V; Briem H; Boemer U; Nguyen D; Husemann M; Hillig RC
Acta Crystallogr D Biol Crystallogr; 2011 Mar; 67(Pt 3):156-66. PubMed ID: 21358046
[TBL] [Abstract][Full Text] [Related]
11. 7-(4H-1,2,4-Triazol-3-yl)benzo[c][2,6]naphthyridines: a novel class of Pim kinase inhibitors with potent cell antiproliferative activity.
Pierre F; Stefan E; Nédellec AS; Chevrel MC; Regan CF; Siddiqui-Jain A; Macalino D; Streiner N; Drygin D; Haddach M; O'Brien SE; Anderes K; Ryckman DM
Bioorg Med Chem Lett; 2011 Nov; 21(22):6687-92. PubMed ID: 21982499
[TBL] [Abstract][Full Text] [Related]
12. Inhibitors of PIM-1 kinase: a computational analysis of the binding free energies of a range of imidazo [1,2-b] pyridazines.
Doudou S; Sharma R; Henchman RH; Sheppard DW; Burton NA
J Chem Inf Model; 2010 Mar; 50(3):368-79. PubMed ID: 20175582
[TBL] [Abstract][Full Text] [Related]
13. Discovery and optimization of triazolopyridazines as potent and selective inhibitors of the c-Met kinase.
Albrecht BK; Harmange JC; Bauer D; Berry L; Bode C; Boezio AA; Chen A; Choquette D; Dussault I; Fridrich C; Hirai S; Hoffman D; Larrow JF; Kaplan-Lefko P; Lin J; Lohman J; Long AM; Moriguchi J; O'Connor A; Potashman MH; Reese M; Rex K; Siegmund A; Shah K; Shimanovich R; Springer SK; Teffera Y; Yang Y; Zhang Y; Bellon SF
J Med Chem; 2008 May; 51(10):2879-82. PubMed ID: 18426196
[TBL] [Abstract][Full Text] [Related]
14. Structure-based design of low-nanomolar PIM kinase inhibitors.
Ishchenko A; Zhang L; Le Brazidec JY; Fan J; Chong JH; Hingway A; Raditsis A; Singh L; Elenbaas B; Hong VS; Marcotte D; Silvian L; Enyedy I; Chao J
Bioorg Med Chem Lett; 2015 Feb; 25(3):474-80. PubMed ID: 25575657
[TBL] [Abstract][Full Text] [Related]
15. Triazolo[1,5-a]pyrimidines as novel CDK2 inhibitors: protein structure-guided design and SAR.
Richardson CM; Williamson DS; Parratt MJ; Borgognoni J; Cansfield AD; Dokurno P; Francis GL; Howes R; Moore JD; Murray JB; Robertson A; Surgenor AE; Torrance CJ
Bioorg Med Chem Lett; 2006 Mar; 16(5):1353-7. PubMed ID: 16325401
[TBL] [Abstract][Full Text] [Related]
16. Discovery of imidazopyridazines as potent Pim-1/2 kinase inhibitors.
Wurz RP; Sastri C; D'Amico DC; Herberich B; Jackson CLM; Pettus LH; Tasker AS; Wu B; Guerrero N; Lipford JR; Winston JT; Yang Y; Wang P; Nguyen Y; Andrews KL; Huang X; Lee MR; Mohr C; Zhang JD; Reid DL; Xu Y; Zhou Y; Wang HL
Bioorg Med Chem Lett; 2016 Nov; 26(22):5580-5590. PubMed ID: 27769621
[TBL] [Abstract][Full Text] [Related]
17. Hit to lead account of the discovery of a new class of inhibitors of Pim kinases and crystallographic studies revealing an unusual kinase binding mode.
Qian K; Wang L; Cywin CL; Farmer BT; Hickey E; Homon C; Jakes S; Kashem MA; Lee G; Leonard S; Li J; Magboo R; Mao W; Pack E; Peng C; Prokopowicz A; Welzel M; Wolak J; Morwick T
J Med Chem; 2009 Apr; 52(7):1814-27. PubMed ID: 19256503
[TBL] [Abstract][Full Text] [Related]
18. Discovery and optimization of pyrrolo[1,2-a]pyrazinones leads to novel and selective inhibitors of PIM kinases.
Casuscelli F; Ardini E; Avanzi N; Casale E; Cervi G; D'Anello M; Donati D; Faiardi D; Ferguson RD; Fogliatto G; Galvani A; Marsiglio A; Mirizzi DG; Montemartini M; Orrenius C; Papeo G; Piutti C; Salom B; Felder ER
Bioorg Med Chem; 2013 Dec; 21(23):7364-80. PubMed ID: 24139169
[TBL] [Abstract][Full Text] [Related]
19. Pim 1 kinase inhibitor ETP-45299 suppresses cellular proliferation and synergizes with PI3K inhibition.
Blanco-Aparicio C; Collazo AM; Oyarzabal J; Leal JF; Albarán MI; Lima FR; Pequeño B; Ajenjo N; Becerra M; Alfonso P; Reymundo MI; Palacios I; Mateos G; Quiñones H; Corrionero A; Carnero A; Pevarello P; Lopez AR; Fominaya J; Pastor J; Bischoff JR
Cancer Lett; 2011 Jan; 300(2):145-53. PubMed ID: 21051136
[TBL] [Abstract][Full Text] [Related]
20. Discovery of 5-substituted-N-arylpyridazinones as inhibitors of p38 MAP kinase.
Jerome KD; Hepperle ME; Walker JK; Xing L; Devraj RV; Benson AG; Baldus JE; Selness SR
Bioorg Med Chem Lett; 2010 May; 20(10):3146-9. PubMed ID: 20395140
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
